| 000 | 01053 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250515063753.0 | ||
| 264 | 0 | _c20070807 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1046-6673 | ||
| 024 | 7 |
_a10.1681/ASN.2007030312 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWarnock, David G | |
| 245 | 0 | 0 |
_aEnzyme replacement therapy and Fabry kidney disease: quo vadis? _h[electronic resource] |
| 260 |
_bJournal of the American Society of Nephrology : JASN _cMay 2007 |
||
| 300 |
_a1368-70 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aFabry Disease _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoenzymes _xtherapeutic use |
| 650 | 0 | 4 |
_aProteinuria _xetiology |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aalpha-Galactosidase _xtherapeutic use |
| 773 | 0 |
_tJournal of the American Society of Nephrology : JASN _gvol. 18 _gno. 5 _gp. 1368-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1681/ASN.2007030312 _zAvailable from publisher's website |
| 999 |
_c16979832 _d16979832 |
||